The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib
Status:
Unknown status
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the influence of epidermal growth factor receptor
mutations on the efficacy of erlotinib and gemcitabine in metastatic pancreatic cancer.